

## 32-1218: LGALS1 Recombinant Protein

### Alternative Name :

Galectin-1, GAL1, GAL-1, Lectin galactoside-binding soluble 1, Beta-galactoside-binding lectin L-14-I, Lactose-binding lectin 1, S-Lac lectin 1, Galaptin, 14 kDa lectin, HPL, HBL, Putative MAPK-activating protein PM12, GBP, DKFZp686E23103.

### Description

Source : Escherichia Coli. LGALS1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 134 amino acids and having a molecular mass of 14.5 kDa. The LGALS1 is purified by proprietary chromatographic techniques. The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Galectin-1 is an autocrine negative growth factor that regulates cell proliferation. Galectin-1 regulates cell apoptosis and cell differentiation. Galectin-1 binds CD45, CD3 and CD4 & inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of lyn kinase. Galectin-1 and its ligands are one of the master regulators of immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation and allergies as well as host-pathogen interactions. Galectin-1 expression or overexpression in tumors and/or the tissue surrounding them must be considered as a sign of the malignant tumor progression that is often related to the long-range dissemination of tumoral cells (metastasis), to their dissemination into the surrounding normal tissue, and to tumor immune-escape. Galectin-1 in its oxidized form plays a number of important roles in the regeneration of the central nervous system after injury. The targeted overexpression (or delivery) of Galectin-1 should be considered as a method of choice for the treatment of some kinds of inflammation-related diseases, neurodegenerative pathologies and muscular dystrophies. In contrast, the targeted inhibition of Galectin-1 expression is what should be developed for therapeutic applications against cancer progression. Galectin-1 is thus a promising molecular target for the development of new and original therapeutic tools. There is 88% homology between the human and mouse galectin-1.

### Product Info

<b>Amount :</b>	50 µg
<b>Purification :</b>	Greater than 95.0% as determined by SDS-PAGE.
<b>Content :</b>	The Galectin-1 protein was lyophilized from a concentrated (1mg/ml) containing 10mM Na <sub>2</sub> PO <sub>4</sub> , pH-7.5.
<b>Storage condition :</b>	Lyophilized Galectin-1 Recombinant although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Galectin-1 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.
<b>Amino Acid :</b>	MACGLVASNL NLKPGECRLRV RGEVAPDAKS FVLNLGKDSN NLCLHFNPRF NAHGDANTIV CNSKDGGAWG TEQREAVFPF QPGSVAEVCITFDQANLTVK LPDGYEFKFP NRLNLEAINY MAADGDFKIK CVAFD.

### Application Note

It is recommended to reconstitute the lyophilized LGALS1 in sterile 18MΩ·cm H<sub>2</sub>O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. The activity of Human Galectin-1 which is determined by the ability to induce chemotaxis of human THP-1 cells is detectable starting at 100ng/ml, corresponding to a specific activity of 1.0x10<sup>4</sup> units/mg.

